⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380085 | 1.00 | — | — | |
| SCHEMBL7379165 | 1.00 | — | — | |
| SCHEMBL8820512 | 0.59 | — | — | |
| SCHEMBL28028202 | 0.57 | — | — | |
| SCHEMBL16611608 | 0.57 | — | — | |
| SCHEMBL555976 | 0.53 | — | — | |
| SCHEMBL18044433 | 0.53 | — | — | |
| SCHEMBL22529636 | 0.53 | — | — | |
| SCHEMBL26278 | 0.53 | — | — | |
| SCHEMBL16294643 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | claimed |
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | claimed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | claimed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | claimed |
| EP-1131320-A1 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000029407-A1 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | claimed |
| US-6476226-B2 | PLATELET GLYCOPROTEIN IIB/IIIA FIBRINOGEN; ANTICOAGULANTS; THROMBOLYTIC AGENTS; THROMBOEMBOLIC DISORDERS; ANTIINFLAMMATORY AGENTS; BONE DISORDERS; ANTITUMOR, -METASTASIS, -ARTHRITIC AGENTS; ASTHMA; PSORIASIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | disclosed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |